Literature DB >> 23132782

Timing of stroke in patients undergoing total hip replacement and matched controls: a nationwide cohort study.

Arief Lalmohamed1, Peter Vestergaard, Cyrus Cooper, Anthonius de Boer, Hubertus G M Leufkens, Tjeerd P van Staa, Frank de Vries.   

Abstract

BACKGROUND AND
PURPOSE: Stroke is a potentially fatal complication of total hip replacements (THR). However, timing of stroke in THR patients compared with matched controls and influence of drug use remain unknown. The objective of this study was to determine timing of stroke in patients with THR compared with matched control subjects.
METHODS: A nationwide cohort study was conducted within the Danish registers (1998-2007). Included patients were those with a primary THR in the study period (n=66,583) and were matched by age, sex, and region to three referent subjects without THR or total knee replacements. Time-dependent Cox models were used to derive hazard ratios and were adjusted for disease history and drug use.
RESULTS: A 4.7-fold increased risk of ischemic stroke (adjusted hazard ratio, 4.69; 95% CI, 3.12-7.06), and a 4.4-fold increased risk of hemorrhagic stroke (adjusted hazard ratio, 4.40; 95% CI, 2.01-9.62) were found within 2 weeks following THR, compared with matched controls. The risk remained elevated during the first 6 postoperative weeks for ischemic stroke, and the first 12 weeks for hemorrhagic stroke. Outpatient antiplatelet drug use lowered the 6-week hazard ratios for ischemic stroke by 70%, although not affecting risk of hemorrhagic stroke.
CONCLUSIONS: This study shows, that THR patients have a 4.7-fold increased risk of ischemic stroke, and a 4.4-fold increased risk of hemorrhagic stroke during the first 2 weeks postsurgery. Risk assessment of stroke in individual patients undergoing THR (ie, evaluate other risk factors for stroke) should be considered during the first 6 to 12 weeks.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23132782     DOI: 10.1161/STROKEAHA.112.668509

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  7 in total

1.  What are the Risk Factors for Cerebrovascular Accidents After Elective Orthopaedic Surgery?

Authors:  Shobhit V Minhas; Preeya Goyal; Alpesh A Patel
Journal:  Clin Orthop Relat Res       Date:  2015-08-20       Impact factor: 4.176

2.  Cerebrovascular disease is associated with outcomes after total knee arthroplasty: a US total joint registry study.

Authors:  Jasvinder A Singh; David G Lewallen
Journal:  J Arthroplasty       Date:  2013-05-10       Impact factor: 4.757

3.  Cerebral fat embolism: Use of MR spectroscopy for accurate diagnosis.

Authors:  Laxmi Kokatnur; Mohan Rudrappa; Khaled R Khasawneh
Journal:  Ann Indian Acad Neurol       Date:  2015 Apr-Jun       Impact factor: 1.383

4.  Efficacy of autologous bone marrow concentrate for knee osteoarthritis with and without adipose graft.

Authors:  Christopher Centeno; John Pitts; Hasan Al-Sayegh; Michael Freeman
Journal:  Biomed Res Int       Date:  2014-09-07       Impact factor: 3.411

5.  Risk of ischemic stroke after discharge from inpatient surgery: Does the type of surgery matter?

Authors:  Cheng-Yang Hsieh; Chin-Wei Huang; Darren Philbert Wu; Sheng-Feng Sung
Journal:  PLoS One       Date:  2018-11-05       Impact factor: 3.240

6.  Statins and Risk of Lower Limb Revision Surgery: The Influence of Differences in Study Design Using Electronic Health Records From the United Kingdom and Denmark.

Authors:  Arief Lalmohamed; Tjeerd P van Staa; Peter Vestergaard; Hubertus G M Leufkens; Anthonius de Boer; Pieter Emans; Cyrus Cooper; Frank de Vries
Journal:  Am J Epidemiol       Date:  2016-06-16       Impact factor: 4.897

7.  Accuracy and utility of using administrative healthcare databases to identify people with epilepsy: a protocol for a systematic review and meta-analysis.

Authors:  Gashirai K Mbizvo; Kyle Bennett; Colin R Simpson; Susan E Duncan; Richard F M Chin
Journal:  BMJ Open       Date:  2018-06-30       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.